Small-cap stocks posted a blistering performance in the first half of this year. The Russell 2000 Index surged 22% through June, marking its strongest first-half performance since ...

The S&P/ASX Small Ordinaries Index (ASX: XSO) closed at 3,390.60, down 6.60 points or 0.19% in the latest session. The index has fallen 2.10% over the past five trading days, reflecting ongoing ...

The S&P/ASX Small Ordinaries Index (XSO) closed at 3,553.80 yesterday, up 0.087% or 3.10 points. The index has gained 4.36% over the past five days, adding 148.50 points as small-cap investor ...

The Russell Microcap Index has more than doubled the performance of the S&P 500 this year.

The S&P/ASX Small Ordinaries Index (XSO) finished slightly weaker yesterday, slipping 5.30 points, or 0.15%, to 3,434.50.

The Russell index reset is usually seen as market plumbing. In 2026, it has become a useful signal for investors watching whether US market leadership is finally spreading beyond mega-cap technology.

Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...

The market for anti-obesity drugs seems to be at risk of calcifying into a dominant duopoly. Eli Lilly(NYSE: LLY) and Novo Nordisk(NYSE: NVO) split it through their GLP-1 medicines: Zepbound ...

The designation could threaten a key revenue stream for the drug contractor and complicate research, manufacturing and supply ...

Stocks like Krishna Institute of Medical Sciences, Dr Reddys Laboratories, Ashoka Buildcon, JSW Energy, Aurobindo Pharma, Power Grid Corporation of India, RBL Bank, SEPC, and IPCA Laboratories will be ...